麻豆AV

An innovative study at the Research Institute of the MUHC has brought
us closer to an explanation for Crohn's disease

Twenty-five per cent of Crohn's disease patients have a mutation in what is called the NOD2 gene, but it is not precisely known how this mutation influences the disease. The latest study by Dr. Marcel Behr, of the Research Institute of the MUHC and 麻豆AV University, has provided new insight into how this might occur. The study will be published on July 9th in the Journal of Experimental Medicine.

When the NOD2 gene functions normally, it codes for a receptor that will recognize invading bacteria and then trigger the immune response. This study demonstrates that the NOD2 receptor preferentially recognizes a peptide called N-glycolyl-MDP, which is only found in a specific family of bacteria called mycobacteria. When mycobacteria invade the human body, they cause an immediate and very strong immune response via the NOD2 receptor.

"Now that we have a better understanding of the normal role of NOD2, we think that a mutation in this gene prevents mycobacteria from being properly recognized by the immune system," explained Dr. Behr. "If mycobacteria are not recognized, the body cannot effectively fight them off and then becomes persistently infected."

Researchers were already aware of the relationship between mycobacteria and Crohn's disease, but they did not know whether the presence of bacteria was a cause or a consequence of the disease. This new discovery associates the predisposition for Crohn's disease with both the NOD2 mutation and the presence of mycobacteria, but researchers must still determine the precise combination of these factors to understand how the disease develops.

More research is required to establish a complete explanation. From this, it is expected that new therapeutic approaches that fight the cause of Crohn's disease may be developed.

Dr. Marcel Behr
Dr. Marcel Behr is a researcher in the Infection and Immunity Axis at the Research Institute of the MUHC and an Associate Professor of Medicine and William Dawson Scholar of 麻豆AV.

Funding
This study was funded by a grant from the Canadian Institutes of Health Research (CIHR). The salaries of some researchers were provided by the Fonds de la recherche en sant茅 du Qu茅bec.

Partners
This article was co-authored by Fran莽ois Coulombe, Maziar Divanghi, Fr茅d茅ric Veyrier, Louis de L茅s茅leuc, Dr. Michael B. Reed and Dr Marcel Behr from the Research Institute of the MUHC; James L. Gleason of 麻豆AV; and Yibin Yang, Michelle A. Kelliher, Amit K. Pandey, and Christopher M. Sassetti of the University of Massachusetts Medical School.


L'Institut de recherche du Centre universitaire de sant茅 麻豆AV (IR CUSM) est un centre de recherche de r茅putation mondiale dans le domaine des sciences biom茅dicales et des soins de sant茅. 脡tabli 脿 Montr茅al, au Qu茅bec, il constitue la base de recherche du CUSM, centre hospitalier universitaire affili茅 脿 la Facult茅 de m茅decine de l'Universit茅 麻豆AV. L'Institut compte plus de 600 chercheurs, pr猫s de 1 200 茅tudiants dipl么m茅s et postdoctoraux et plus de 300 laboratoires de recherche consacr茅s 脿 un large 茅ventail de domaines de recherche, fondamentale et clinique. L'Institut de recherche est 脿 l'avant-garde des connaissances, de l'innovation et de la technologie. La recherche de l'Institut est 茅troitement li茅e aux programmes cliniques du CUSM, ce qui permet aux patients de b茅n茅ficier directement des connaissances scientifiques les plus avanc茅es.
L'Institut de recherche du CUSM est soutenu en partie par le Fonds de la recherche en sant茅 du Qu茅bec.
Pour de plus amples renseignements, consulter l'adresse .


Pour de plus amples renseignements, veuillez contacter :

Isabelle Kling
Coordonnatrice des communications (Recherche)
Relations publiques et Communications, CUSM
(514) 843 1560
isabelle.kling [at] muhc.mcgill.ca